Toll-like receptors in kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 3, 2009, Pages 189-196

  Smith, Kelly D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Autoimmunity; Endogenous agonists; Inflammation; Innate immunity; Sterile injury; Toll like receptors

Indexed keywords

AUTOANTIBODY; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; CELL DEATH; ENVIRONMENTAL FACTOR; GLOMERULONEPHRITIS; HUMAN; INNATE IMMUNITY; KIDNEY DISEASE; KIDNEY INFECTION; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANIMAL; DRUG POTENTIATION; ENVIRONMENT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ENVIRONMENT; HUMANS; IMMUNITY, INNATE; KIDNEY DISEASES; TOLL-LIKE RECEPTORS;

EID: 67049169040     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32832a1d5f     Document Type: Review

References (63)

1. Jin MS, Kim SE, Heo JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007; 130:1071-1082.
2. Kim HM, Park BS, Kim JI, et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran. Cell 2007; 130:906-917.
3. Liu L, Botos I, Wang Y, et al. Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. Science 2008; 320:379-381.
4. Song J, Abraham SN. TLR-mediated immune responses in the urinary tract. Curr Opin Microbiol 2008; 11:66-73.
5. Cirl C, Wieser A, Yadav M, et al. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. Nat Med 2008; 14:399-406.
6. *]
7. *]) describe patients with homozygous deficiencies in MyD88 or IRAK4, and the susceptibility of these individuals to infections by primarily Streptococcus pneumoniae and some additional pyogenic bacteria.
8. Guay HM, Andreyeva TA, Garcea RL, et al. MyD88 is required for the formation of long-term humoral immunity to virus infection. J Immunol 2007; 178:5124-5131.
9. Wornle M, Schmid H, Banas B, et al. Novel role of Toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol 2006; 168:370-385.
10. Schott E, Witt H, Neumann K, et al. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy. J Viral Hepat 2008; 15:71-78.
11. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 2007; 82:479-487.
12. Hou B, Reizis B, DeFranco AL Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity 2008; 29:272-282. These authors have generated a conditional knockout of MyD88 and use it in this study to demonstrate that this mouse will be very useful for dissecting cell-type-specific contributions of the TLR pathway to kidney disease.
13. Ramesh G, Reeves WB. Inflammatory cytokines in acute renal failure. Kidney Int Suppl 2004; 91:S56-S61.
14. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int 2004; 66:480-485.
15. Leemans JC, Stokman G, Claessen N, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005; 115:2894-2903.
16. **]) provide compelling evidence that TLR2 and TLR4 contribute to inflammatory injury that is triggered during IRI in mice. Circumstantial evidence is introduced to support the role of endogenous agonists, which warrant further investigation. Conflicting data about the role of TLR signaling adaptor MyD88 are also presented.
17. **]) provide compelling evidence that TLR2 and TLR4 contribute to inflammatory injury that is triggered during IRI in mice. Circumstantial evidence is introduced to support the role of endogenous agonists, which warrant further investigation. Conflicting data about the role of TLR signaling adaptor MyD88 are also presented.
18. **]) provide compelling evidence that TLR2 and TLR4 contribute to inflammatory injury that is triggered during IRI in mice. Circumstantial evidence is introduced to support the role of endogenous agonists, which warrant further investigation. Conflicting data about the role of TLR signaling adaptor MyD88 are also presented.
19. Zhang B, Ramesh G, Uematsu S, et al. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 2008; 19:923-932.
20. Takeuchi O, Kaufmann A, Grote K, et al. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopep-tide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway. J Immunol 2000; 164:554-557.
21. Takeuchi O, Kawai T, Muhlradt PF, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001; 13:933-940.
22. Takeuchi O, Sato S, Horiuchi T, et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169:10-14.
23. Zahringer U, Lindner B, Inamura S, et al. TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 2008; 213:205-224.
24. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004; 76:514-519.
25. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007; 19:3-10.
26. Finberg RW, Wang JP, Kurt-Jones EA. Toll like receptors and viruses. Rev Med Virol 2007; 17:35-43.
27. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-738.
28. Kariko K, Ni H, Capodici J, et al. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004; 279:12542-12550.
29. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-2088.
30. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220:47-59.
31. Saemann MD, Weichhart T, Zeyda M, et al. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J Clin Invest 2005; 115:468-475.
32. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410: 1099-1103.
33. Coban C, Ishii KJ, Kawai T, et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med 2005; 201:19-25.
34. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-745.
35. Yarovinsky F, Zhang D, Andersen JF, et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005; 308:1626-1629.
36. Roach JC, Glusman G, Rowen L, et al. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 2005; 102:9577-9582.
37. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8:279-289.
38. Tsan MF, Baochong G. Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors. J Endotoxin Res 2007; 13:6-14.
39. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290:C917-C924.
40. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8:487-496.
41. Youn JH, Oh YJ, Kim ES, et al. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 2008; 180:5067-5074.
42. Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115:2223-2233.
43. Herlands RA, Christensen SR, Sweet RA, et al. T cell-independent and Toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 2008; 29:249-260. This study elucidates the mechanism, whereby TLR agonists as components of immune complexes initiate the development of rheumatoid factor-producing B cells, independent of T cells and outside of B-cell follicles.
44. Allam R, Anders HJ. The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol 2008; 20:538-544.
45. Christensen SR, Shupe J, Nickerson K, et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006; 25:417-428.
46. Deane JA, Pisitkun P, Barrett RS, et al. Control of Toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007; 27:801-810.
47. Fairhurst AM, Hwang SH, Wang A, et al. Yaa autoimmune phenotypes are conferred by overexpression of TLR7. Eur J Immunol 2008; 38:1971-1978.
48. Lee PY, Kumagai Y, Li Y, et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 2008; 205:2995-3006.
49. Savarese E, Steinberg C, Pawar RD, etal. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 2008; 58:1107-1115.
50. Liu B, Yang Y, Dai J, et al. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol 2006; 177:6880-6888.
51. Lech M, Kulkarni OP, Pfeiffer S, et al. TIR8/SIGIRR prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 2008; 205:1879-1888.
52. Fu Y, Xie C, Chen J, et al. Innate stimuli accentuate end-organ damage by nephrotoxic antibodies via Fc receptor and TLR stimulation and IL-1/TNF-alpha production. J Immunol 2006; 176:632-639.
53. Anders HJ, Banas B, Linde Y, et al. Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors. J Am Soc Nephrol 2003; 14:317-326.
54. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 2004; 118:229-241.
55. Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289:2350-2354.
56. Turer EE, Tavares RM, Mortier E, et al. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J Exp Med 2008; 205:451-464. This study demonstrates that TLRs are constantly exposed to signals from commensal bacteria and that TNFAIP3 (A20) is a crucial negative regulator of this tonic activation of TLR signaling.
57. Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008; 40:1062-1064.
58. Isnardi I, Ng YS, Srdanovic I, et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008; 29:746-757. These authors find that patients with deficiencies in MyD88 or IRAK4 fail to delete autoreactive B lymphocytes, suggesting that interactions between TLRs and the environment regulate B-cell development.
59. Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 2008; 455:1109-1113.
60. Yu HB, Finlay BB. The caspase-1 inflammasome: a pilot of innate immune responses. Cell Host Microbe 2008; 4:198-208.
61. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol 2008; 20:17-22.
62. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241.
63. Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440:228-232.